Impax Seeks To Pop Pimple-Fighting Patent

Law360, New York (January 16, 2008, 12:00 AM EST) -- Impax Laboratories Inc. is challenging Medicis Pharmaceutical Corp.'s patent for a popular acne medication in hopes of launching a generic version of the drug.

Impax announced on Tuesday that it had filed a lawsuit against Medicis in the U.S. District Court for the Northern District of California to fend off a patent challenge for a generic version of the acne drug Solodyn.

The declaratory judgment suit claims that Impax's October 2007 Abbreviated New Drug Application with the U.S. Food and Drug Administration for minocycline hydrochloride extended-release...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.